You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 168 No. 8, April 28, 2008 TABLE OF CONTENTS
  Archives
  •  Online Features
  Original Investigation
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Related articles
 •Similar articles in this journal
 Topic Collections
 •Osteoporosis
 •Women's Health
 •Women's Health, Other
 •Aging/ Geriatrics
 •Arrhythmias
 •Adverse Effects
 •Alert me on articles by topic

Use of Alendronate and Risk of Incident Atrial Fibrillation in Women

Arch Intern Med. 2008;168(8):826-831.

Background  A recent publication from the HORIZON (Health Outcomes and Reduced Incidence With Zoledronic Acid Once Yearly) trial in women with postmenopausal osteoporosis reported a higher risk of serious atrial fibrillation (AF) in zoledronic acid recipients than in placebo recipients. This adverse effect was unexpected and had not been recognized previously.

Methods  We studied alendronate sodium ever use in relation to the risk of incident AF in women in a clinical practice setting. This population-based case-control study was conducted at Group Health, an integrated health care delivery system in Washington State. We identified 719 women with confirmed incident AF between October 1, 2001, and December 31, 2004, and 966 female control subjects without AF, selected at random from the Group Health enrollment and frequency matched on age, presence or absence of treated hypertension, and calendar year.

Results  More AF case patients than controls had ever used alendronate (6.5% [n = 47] vs 4.1% [n = 40]; P = .03). Compared with never use of any bisphosphonate, ever use of alendronate was associated with a higher risk of incident AF (odds ratio, 1.86; 95% confidence interval, 1.09-3.15) after adjustment for the matching variables, a diagnosis of osteoporosis, and a history of cardiovascular disease. Based on the population-attributable fraction, we estimated that 3% of incident AF in this population might be explained by alendronate use.

Conclusion  Ever use of alendronate was associated with an increased risk of incident AF in clinical practice.


Author Affiliations: Cardiovascular Health Research Unit (Drs Heckbert, Smith, and Psaty and Mr Li) and Departments of Epidemiology (Drs Heckbert, Smith, and Psaty) and Medicine (Mr Li and Dr Psaty), University of Washington, Seattle; Center for Health Studies, Group Health, Seattle (Drs Heckbert and Psaty); San Francisco Coordinating Center, California Pacific Medical Center Research Institute and University of California, San Francisco (Dr Cummings); and Seattle Epidemiologic Research and Information Center, Veterans Administration Puget Sound Health Care System, Seattle (Dr Smith).


RELATED ARTICLES

Considering Competing Risks . . . Not All Black and White
Jane A. Cauley and Kristine E. Ensrud
Arch Intern Med. 2008;168(8):793-795.
EXTRACT | FULL TEXT  

Use of Thiazolidinediones and Fracture Risk
Christian Meier, Marius E. Kraenzlin, Michael Bodmer, Susan S. Jick, Hershel Jick, and Christoph R. Meier
Arch Intern Med. 2008;168(8):820-825.
ABSTRACT | FULL TEXT  


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Alendronate and Risk for Atrial Fibrillation
JWatch General 2008;2008:4-4.
FULL TEXT  

Considering Competing Risks . . . Not All Black and White
Cauley and Ensrud
Arch Intern Med 2008;168:793-795.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2008 American Medical Association. All Rights Reserved.